

NANEMIAR

**Nanomedicine Approach to Normalize
Erythrocyte Maturation in Congenital
Anemia by messenger RNA**

PROJECT INFORMATION SHEET

PROJECT FACTS

Duration

01/10/2023 to 28/02/2027 (41 months)

Programme

HORIZON Europe - The European Union's Horizon Europe Research and Innovation Programme 2021-2027

Type of Action

HORIZON Research and Innovation Action (RIA)

Grant Agreement

101080156

Project partners

1. Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS) - Spain (**Coordinator**)
 - Servicio Murciano de Salud (Affiliated Entity to FFIS) - Spain
2. Mercurna BV (Mercurna BV) - The Netherlands
3. Centre National de la Recherche Scientifique (CNRS) - France

Max. grant amount

2.682.897,50€

Keywords

Biochemistry and molecular biology, mRNA, lipid nanoparticles, targeted delivery, erythrocytosis, congenital anemia

PROJECT SUMMARY

Messenger RNA (mRNA) is a versatile tool known for its rapid development, high effectiveness, and low risk. In the NANEMIAR project, we will harness the advantages of mRNA to develop a treatment for congenital anemia.

Ambition



Development of an mRNA-based drug candidate for treatment of congenital anemias

Specific objectives



Development of targeted mRNA therapeutic


Pharmaceutical application of mRNA therapeutic



Pre-clinical potential of novel therapeutic


Combining expertise from academic, clinical and industry partners in Spain, France and The Netherlands, we aim to generate an innovative treatment option for congenital anemia, and advance knowledge in targeted therapeutics.

Outcomes of the call



A nanomedicine base-system for next-generation gene therapies

Proof-of-concept for a safe treatment option for b-thalassemia




Expected impact



“Health burden of diseases in the EU and worldwide is reduced through effective disease management”

Aligning with The Horizon Europe Strategic Plan for improved therapies and rare diseases.



NANEMIAR



**Funded by the
European Union**

This project has received funding from the European Union's Horizon Europe research and innovation programme 2021- 2027 under the Grant Agreement No 101080156

PARTNERS:



ALHETA supports and appreciates these research efforts.



Spanish Association for the Fight against Hemoglobinopathies and Thalassemias